Eckert & Ziegler Logo
DE0005659700
565970
EUZ.DE

Eckert & Ziegler

Cargando cotizaciones...

Previsión

No hay datos de analistas disponibles para esta empresa.

Debates en la comunidad

  • Aktiensplit: Eckert & Ziegler Strahlen (DE0005659700)

    Sumit Sumit IV en Schnack

    2 11

  • Eckert und Ziegler needs positive Q3 impulses to break downtrend

    The stock of Eckert und Ziegler has moved up from its yearly low but remains in a medium- to long-term downtrend. Analysts at NuWays expect an acceleration of earnings growth ahead of the Q3 results on November 12, driven by higher profitability in the Isotope Products division as well as rising sales of lutetium‑177 and licence income. Technically, the stock must overcome short-term hurdles around €13, just under €14 and the 200-day line at roughly €14.40; on the downside it needs to hold €12.50/€12.60, otherwise a retest of the yearly low at €12 looms. » Más en finanzen.net


  • Eckert & Ziegler signs supply agreement for terbium-161 with TerThera

    Eckert & Ziegler has signed an agreement with Dutch provider TerThera for the supply of the radionuclide terbium-161 for radioligand therapies. Terbium-161 is to be added to Eckert & Ziegler’s portfolio in Brazil to shorten the supply chain and improve regional access to theranostic solutions. The news helped the stock move off its year low, but a sustainable bottoming has not yet been achieved. » Más en finanzen.net


  • Eckert und Ziegler confirms 2026 targets, stock remains under pressure

    Eckert und Ziegler has once again confirmed its targets for 2026: revenue around €320 million and adjusted EBIT of about €80 million. Investors are responding cautiously, the stock is generally moving downward and the chart technicals signal further pressure. Adjusted for currency effects and the licensing business, reported revenue and earnings show growth, but real growth is significantly more moderate. » Más en finanzen.net


  • Eckert und Ziegler face further share losses due to geopolitical risks and missed targets

    Geopolitical tensions in the Gulf are raising energy costs and making transport and logistics more expensive for Eckert und Ziegler, which could dampen demand. Adjusted EBIT after H1 was €33.3m, well below the annual target of around €80m, and revenue has reached €149.3m of the roughly planned €320m. Given this development, strong Q3 figures are unlikely; the stock has been in a downtrend since July and could technically fall from support at around €12.20 to just under €11, though single‑digit prices still appear distant. » Más en finanzen.net


  • Eckert & Ziegler disappoints with half-year figures and breaks chart support

    Eckert & Ziegler reported only modest revenue growth in the first half of 2026 to €149.3m, with adjusted EBIT down 6% to €33.3m. Targets for 2026 were confirmed, but reaching an adjusted EBIT of around €80m could become riskier after delays in gallium-generator deliveries caused by a cyber attack and a weak Isotope Products segment. The share fell through repeatedly tested levels and broke support at €13.30, putting a further decline toward about €12.40 at risk. Long term, the potential remains intact thanks to large actinium-225 capacities and expansion opportunities in China. » Más en finanzen.net

En 2026, Eckert & Ziegler ya ha pagado 0,22 € en dividendos. El último pago fue en junio.

Datos financieros de la empresa

En el último trimestre, Eckert & Ziegler tuvo unos ingresos de 79,6 M € y un beneficio neto de 13,1 M €
(EUR) septiembre de 2026
YoY
Ingresos 79,6 M 5,69 %
Beneficio bruto 0 100,00 %
Beneficio neto 13,1 M 54,90 %
EBITDA 19,3 M 0,47 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
959,92 M €
Número de acciones
62,58 M
Máximo/mínimo de 52 semanas
16,84 € - 11,91 €
Rentabilidad por dividendo
1,43 %
Dividendos TTM
0,22 €
Beta
1,47
Ratio P/E
17,63
Ratio PEG
0,49
Ratio P/B
3,58
Ratio P/S
3,03

Perfil de la empresa

Eckert & Ziegler Strahlen- und Medizintechnik AG, a través de sus filiales, fabrica y vende componentes de tecnología de isótopos para aplicaciones médicas, científicas e industriales en todo el mundo. Opera en dos segmentos, Medical e Isotope Products. El segmento Medical ofrece implantes radiactivos pequeños para el tratamiento del cáncer de próstata, en forma de semillas, y aplicaciones oculares basadas en rutenio-106 o yodo-125 para el tratamiento del melanoma uveal. Este segmento también proporciona radiofármacos, equipos de laboratorio, celdas calientes y servicios para radiofármacos, así como aplicadores oculares e implantes de próstata. El segmento Isotope Products fabrica y vende fuentes de radiación para imagen, tecnología de medición, análisis de materiales, garantía de calidad y monitorización ambiental. Este segmento también ofrece fuentes de calibración para sistemas de imagen médica, y productos para seguridad nacional y medición radiométrica de nivel. La empresa fue fundada en 1992 y tiene su sede en Berlín, Alemania.

Nombre
Eckert & Ziegler
CEO
Harald Hasselmann
Sede Berlin, be
Alemania
Sitio web
Sector
Salud
Industria
Tecnología sanitaria
Salida a bolsa
26/05/1999
Empleados 1116

Símbolos bursátiles

Bolsa Símbolo
XETRA
EUZ.DE
Frankfurt
EUZ.F
Düsseldorf
EUZ.DU
Hamburg
EUZ.HM
Milan
1EUZ.MI
London
0NZY.L
SIX
EUZ.SW
München
EUZ.MU
🍪

Parqet  usa cookies. Más información